Halozyme Therapeutics (HALO) Tops Q1 EPS by 10c, Beats on Revenue; Offers Guidance
Tweet
Share
E-mailGet Alerts HALO Hot Sheet
Price: $112.45 +2.53%
Revenue Growth %: +36.2%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Revenue Growth %: +36.2%
Financial Fact:
Operating income (loss): -22.74M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.79, $0.10 better than the analyst estimate of $0.69. Revenue for the quarter came in at $196 million versus the consensus estimate of $199.74 million.
GUIDANCE:
Halozyme Therapeutics sees FY2024 EPS of $3.55-$3.90. Halozyme Therapeutics sees FY2024 revenue of $915-985 million.
For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Vera Bradley (VRA) Tops Q2 EPS by 10c ; Offers Guidance
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
